Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Expectations By $0.21 EPS

Vericel (NASDAQ:VCEL) released its quarterly earnings results on Thursday. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.21, Zacks reports. The firm had revenue of $85.37 million for the quarter, compared to the consensus estimate of $77.95 million. Vericel had a return on equity of 6.91% and a net margin of 7.91%. The firm’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.10 EPS.

Here are the key takeaways from Vericel’s conference call:

• Vericel reported third-quarter revenue of $85.4 million, up 26%, and raised 2026 revenue guidance to $344 million–$346 million after results exceeded expectations. The company also raised adjusted EBITDA margin guidance to approximately 28%.
• MACI revenue grew 21% to a record $67.4 million, with records for biopsies, implants, and participating surgeons; October also brought the strongest biopsy month since launch. Management cited sales-force expansion, deeper surgeon engagement, and MACI Arthro adoption as growth drivers, while noting that biopsies convert to procedures over time.
• Burn-care revenue reached a record $18 million, up 52%, with record quarterly revenue for both Epicel and commercial NexoBrid. Management attributed Epicel’s strength mainly to commercial execution, while acknowledging that burn-care results can be variable and that the number of severe burns is outside the company’s control.
• Profitability and cash generation strengthened: adjusted EBITDA rose 48% to $25.2 million, free cash flow was $16 million, and the company ended the quarter with $236 million in cash and investments and no debt. Vericel said it remains on track with its longer-term targets, while continuing investments in growth and exploring both share repurchases and business development.

Vericel Price Performance

Shares of NASDAQ:VCEL traded up $2.84 during trading on Friday, reaching $54.62. The company had a trading volume of 1,612,332 shares, compared to its average volume of 564,100. Vericel has a fifty-two week low of $28.95 and a fifty-two week high of $55.60. The stock’s fifty day moving average price is $41.01 and its 200 day moving average price is $38.90. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of 85.35 and a beta of 1.08.

Insider Buying and Selling

In other Vericel news, insider Jonathan Siegal sold 1,500 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $52.90, for a total value of $79,350.00. Following the transaction, the insider directly owned 1,259 shares of the company’s stock, valued at approximately $66,601.10. The trade was a 54.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $51.92, for a total transaction of $778,800.00. Following the completion of the transaction, the insider directly owned 1,990 shares in the company, valued at $103,320.80. This represents a 88.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 22,000 shares of company stock valued at $1,128,340 over the last three months. 7.60% of the stock is currently owned by company insiders.

Vericel News Roundup

Here are the key news stories impacting Vericel this week:

• Positive Sentiment: Vericel reported Q3 revenue of $85.4 million, up 26.5% year over year and above the $78.0 million consensus. Earnings per share of $0.27 also topped estimates of $0.06, while net income rose 179% to $14.2 million. Vericel Q3 results and guidance
• Positive Sentiment: The company raised its FY2026 revenue outlook to $344 million–$346 million, above analyst expectations of roughly $336 million, and lifted its adjusted EBITDA margin guidance to 28%. The stronger outlook, alongside record MACI sales, helped fuel investor optimism. Vericel shares rise on record revenue and higher outlook
• Positive Sentiment: HC Wainwright raised its price target to $75 from $72 and maintained a Buy rating, signaling continued analyst confidence in the stock’s prospects. HC Wainwright price target update
• Negative Sentiment: Several Vericel directors and insiders disclosed stock sales totaling about 22,000 shares on November 4–5. One insider’s sale reduced their reported stake by 88%, which may be a near-term concern for investors, though insider sales alone do not establish a negative outlook. SEC insider transaction filing

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on VCEL shares. Weiss Ratings reissued a “hold (c)” rating on shares of Vericel in a report on Thursday, October 29th. Wall Street Zen upgraded shares of Vericel from a “buy” rating to a “strong-buy” rating in a research note on Saturday. HC Wainwright raised their price objective on shares of Vericel from $72.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday. Truist Financial set a $65.00 price objective on shares of Vericel in a research note on Friday. Finally, Canaccord Genuity Group set a $60.00 price objective on shares of Vericel in a research note on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $60.80.

Vericel Company Profile

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.